HER2+ Breast Cancer | Specialty

Dr. Hahn on the Convenience of Subcutaneous Trastuzumab/Pertuzumab in HER2+ Breast Cancer

April 30th 2021

Olwen Hahn, MD, discusses the convenience of the fixed-dose combination of trastuzumab and pertuzumab in a subcutaneous formulation in HER2-positive breast cancer.

Dr. Meisel on Sequencing Therapies in Metastatic HER2+ Breast Cancer

April 21st 2021

Jane L. Meisel, MD, discusses sequencing therapies for patients with metastatic HER2-positive breast cancer.

NICE Recommends Trastuzumab Deruxtecan in Advanced HER2+ Breast Cancer

April 20th 2021

The National Institute for Health and Care Excellence has published draft guidance that recommends fam-trastuzumab deruxtecan-nxki for the treatment of patients with unresectable or metastatic HER2-positive breast cancer following 2 or more anti-HER2 therapies.

Dr. Meisel the Potential Utility of CDK4/6 Inhibitors in HER2+ Breast Cancer

April 16th 2021

Jane L. Meisel, MD, discusses the potential utility of CDK4/6 inhibitors in HER2-positive metastatic breast cancer.

Future Is Wide Open for HER2+ Breast Cancer

April 12th 2021

As longer-term follow-up data become available for several agents approved for HER2-positive metastatic breast cancer, investigators are looking closely at the characteristics of patients enrolled in those clinical trials to determine appropriate treatment strategies in the third-line setting and beyond.

Dr. Wei on the Risk of ILD With Trastuzumab Deruxtecan in HER2+ Breast Cancer

April 9th 2021

Mei Wei, MD, discusses the risk of interstitial lung disease with fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Research Efforts in HER2+ Breast Cancer Pick Up Speed Despite COVID-19

April 9th 2021

Jane L. Meisel, MD, discusses sequencing questions, tucatinib combinations under exploration, and emerging strategies for use in the treatment of patients with HER2-positive breast cancer.

Dr. Meisel on Managing Toxicities Associated with T-DM1 in HER2+ Breast Cancer

April 6th 2021

Jane L. Meisel, MD, discusses managing toxicities associated with ado-trastuzumab emtansine in patients with HER2-positive breast cancer.

Experts Take a Fresh Look at Strategies for Early-Stage HER2+ Breast Cancer

April 5th 2021

Although trastuzumab-based regimens remain the standard treatment for patients with early-stage HER2-positive breast cancer, unanswered clinical questions surround the use of other agents in the neoadjuvant and adjuvant settings.

Meisel on Managing Toxicities With T-DM1 in HER2+ Breast Cancer

April 3rd 2021

Data from the pivotal phase 3 KATHERINE has led to the addition of ado-trastuzumab emtansine to the HER2-positive breast cancer treatment arsenal, but the toxicities associated with the approach must be appropriately managed so that patients can continue to receive it.

Dr. Meisel on the Nuances of Utilizing Adjuvant T-DM1 in HER2+ Breast Cancer

April 2nd 2021

Jane L. Meisel, MD, discusses some of the nuances of utilizing adjuvant ado-trastuzumab emtansine in HER2-positive breast cancer.

Experts Take Stock of New CNS Data for HER2+ Metastatic Breast Cancer

March 18th 2021

Findings from recent analyses have kindled hope that novel agents with manageable toxicity profiles may begin to bridge the gap for patients with HER2-positive metastatic breast cancer.

Defining Value for the Treatment of Brain Metastases in Metastatic HER2-Positive Breast Cancer

March 8th 2021

Experts highlight the risk factors, comorbidities, diagnosis, economic burden, and treatments for brain metastasis in metastatic breast cancer based on data presented at the 2020 San Antonio Breast Cancer Symposium.

Personalizing HER2-Targeted Treatment Strategies in Early-Stage and Advanced Breast Cancer

March 5th 2021

Debu Tripathy, MD, discusses some of the unanswered clinical questions that remain for patients with HER2-positive disease and some strategies for personalizing treatment in the neoadjuvant and adjuvant settings.

Targeted Therapies Continue to Shape Future Breast Cancer Paradigm

March 5th 2021

With the identification of numerous molecular abnormalities that can affect treatment and the course of disease in patients with breast cancer, it’s become understood that genetic profiling can define clinical trial eligibility, the presence or absence of aberrations help to drive treatment decisions, and variants can be predictive for response or resistance.

Decision Factors for SubQ Therapy and Unmet Needs

March 5th 2021

New Indications in HER2+ Breast Cancer Spark Discussions on Selection, Safety, and Sequencing

March 4th 2021

The KATHERINE, FeDeriCa, DESTINY-Breast01, and HER2CLIMB trials have changed practice for patients with HER2-positive breast cancer for the better.

Waisman Walks Through Sequencing Strategy in Metastatic HER2-Positive Breast Cancer

March 4th 2021

James R. Waisman, MD, shares his process for matching patients with the right treatment in the metastatic setting and areas for future exploration.

Dr. Wei on Benefits of Subcutaneous Pertuzumab/Trastuzumab in HER2+ Early Breast Cancer

March 3rd 2021

Mei Wei, MD, discusses the benefits of subcutaneous administration of pertuzumab and trastuzumab in patients with HER2-positive early breast cancer.

Antibody-Drug Conjugates, TKIs Drive Improved Outcomes in HER2+ Breast Cancer

March 3rd 2021

The practice-changing treatment regimens that were evaluated in the pivotal KATHERINE, HER2CLIMB, and DESTINY-Breast01 trials in women with HER2-positive breast cancer are pushing the needle forward in making this breast cancer subtype a chronic disease.